Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

782
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
782
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

531
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
531

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Authorship and citation trends in dementia research: A path to equitable career development for scientists.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Predicting the timing of first sustained cognitive worsening in Alzheimer's disease using real-world clinical data and machine learning.

medRxiv : the preprint server for health sciences·2026
Same author

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026
Same author

CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.

medRxiv : the preprint server for health sciences·2026
Same author

Complex interplay of astrogliosis and pathology in preclinical Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.2K

Biomarkers.

Laura Alejandra Ramirez Tirado1, Ann D Cohen1,2,3, C Elizabeth Shaaban1,2

  • 1University of Pittsburgh, Pittsburgh, PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|January 13, 2026
PubMed
Summary
This summary is machine-generated.

Peripheral inflammation markers (TNFR1, TNFR2) combined with astrogliosis (GFAP) significantly increase Alzheimer's disease dementia risk and mortality in amyloid-beta positive individuals.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

744

Related Experiment Videos

Last Updated: Jan 14, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.2K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

744

Area of Science:

  • Neuroscience
  • Immunology
  • Gerontology

Background:

  • Previous research indicated synergistic effects of Tumor Necrosis Factor Receptor 1 (TNFR1) and TNFR2 with astrogliosis, leading to increased vascular burden and neurodegeneration, especially in amyloid-beta positive (Aβ+) individuals.
  • This study investigates the combined impact of peripheral inflammation and astrogliosis on the incidence of Alzheimer's disease (AD) dementia and mortality.

Purpose of the Study:

  • To assess the interaction between peripheral inflammation markers (TNFR1, TNFR2) and astrogliosis (GFAP) in predicting AD dementia incidence and mortality.
  • To test the hypothesis that synergistic effects between astrogliosis and peripheral inflammation accelerate dementia progression and increase mortality, particularly in Aβ+ participants.

Main Methods:

  • Utilized data from the Gingko Evaluation of Memory (GEM) study, including PiB-PET scans, GFAP, and peripheral inflammatory markers (TNFR1, TNFR2) measured via immunoassay.
  • Employed Cox proportional hazards models to evaluate the relationship between inflammation, astrogliosis, and outcomes, adjusting for key covariates including age, sex, education, APOEε4, cystatin C, and baseline Aβ status.

Main Results:

  • In Aβ+ participants, combined high levels of GFAP with TNFR1 or TNFR2 showed significant additive and multiplicative interactions, increasing dementia hazards (TNFR1: HR 4.55, p=.032; TNFR2: HR 4.07, p=.012).
  • High TNFR1 levels were associated with increased mortality risk (HR 1.50, p=.046), and synergistic effects on mortality were observed between GFAP and TNFR2 in Aβ+ individuals (p=0.036).
  • While Aβ+ status independently increased dementia risk (HR 1.73, p=.016), TNFR1 and TNFR2 alone did not significantly predict dementia incidence after full adjustment.

Conclusions:

  • The interaction between astrogliosis (GFAP) and peripheral inflammation (TNFR1, TNFR2) is clinically significant for predicting AD dementia progression and mortality in Aβ+ individuals.
  • These findings highlight the critical role of combined inflammatory and glial activation pathways in driving AD pathogenesis and outcomes.